

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

**Notices:**

- License integration enhancement has been postponed. The launch was not successful
- We are working with Appriss on being able to issue automatic compliance notifications to providers who directly dispense, letting them know if they miss a day of reporting.
- The RFP for the PDMP contract has been issued; proposals are due November 5, 2020.
- The PDMP received two grants: The State Opioid Response (SOR) grant and a partial award of the Bureau of Justice Assistance (BJA) grant.

**Registration**

**Portal**

Number of licensed Nurses: 1,598

Number of PDMP Nursing registrations: 825

**AWARxE (PDMP)**

Number registered with the PDMP: 1,109 (6% increase from August 2020)

Compliance rate: 69% (2% increase since August 2020)

**Use**

Review compliance from June – October 2020: 49.5% (2% increase from August 2020)

**MME Use (April 2020 – September 2020)**

Number of patients treated with over 90 MME: 269 (30% decrease from October 2019 – March 2020)

Number of patients treated with over 120 MME: 94 (41% decrease from October 2019 – March 2020)

Number of patients treated with dangerous combinations (benzodiazepines and opioids): 518 (82% decrease from October 2019 – March 2020)

Number of patients treated with dangerous combinations (benzodiazepines, opioids, carisoprodol): 7 (87% decrease from October 2019 – March 2020)

**Delinquent Reporters**

Providers who directly dispense are required to report daily. We are currently gathering this information on the renewal applications.

**Recommendations**

- Encourage increased reviewing, including the use of delegates
- Set daily MME in regulation
- Provide guidance to licensees on prescribing practices related to the use of dangerous combinations
- Providers should be notified they are not able to prescribe until their registration in AWARxE have been approved.
- Encourage licensees to verify their user roles and specialties in AWARxE to improve the accuracy of reporting.
- Clarify registration regulation – Prescriptive Authority and DEA registration

**PDMP Overview  
 Registration**




Figure 1A. Physician includes those registered as Physician, Podiatrist, and Medical Residents with Prescriptive Authority. \*Other includes IHS, VA, and military prescribers and dispensers, admin, coroners, and out-of-state pharmacists.




Figure 1B. This figure may be underrepresented as there are licensed prescribers inclusive in federal user role categories (IHS Prescriber, VA Prescriber, and Military Prescribers).

**MME Use**

June 2020 – October 2020

The CDC recommends that primary care clinicians should reassess evidence of the benefits and risks to the individual when increasing dosage to greater or equal to 50 MME/day and avoid increasing to greater or equal to 90 MME/day when possible due to an increased risk of complications. The CDC also recommends avoiding concurrent benzodiazepine and opioid prescriptions, given the high risk of adverse drug-drug interactions, specifically respiratory depression and death.

CDC checklist for prescribing opioids -

[https://www.commerce.alaska.gov/web/portals/5/pub/PDMP\\_OpiodPrescribeCDC\\_06.2018.pdf](https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDC_06.2018.pdf)

CDC guidelines for prescribing opioids for chronic pain -

[https://www.commerce.alaska.gov/web/portals/5/pub/PDMP\\_OpiodPrescribeCDCPain\\_2018.10.pdf](https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDCPain_2018.10.pdf)

Provider Type	# Providers Prescribing at Least Once	# Providers Who Reviewed 0 Patients	# Providers Prescribing >90MME	# Providers Prescribing >120MME	Dangerous Combo	
					Benzo Opioid	Benzo Opioid Carisoprodol
NUR	499	22% (112)	12% (59)	7% (37)	25% (124)	1% (7)
DEN	311	60% (187)	5% (17)	1% (4)	26% (80)	0
MED	1354	31% (421)	20% (273)	12% (165)	32% (438)	2.6% (35)
VET	171	76% (130)	2% (4)	2% (4)	6% (10)	0
OPT	2	100% (2)	0	0	0	0